GroveStreet Managing Director, John Merrill, spoke at Invest Canada ‘23 on the evolution of best practices in biotech and healthcare investing. Since the inception of the firm, GroveStreet has been a consistent investor in the space backing many of the leading biotech firms just as they were being formed. While transformational innovations in biotech and healthcare present an array of compelling opportunities to long-term investors, caution and selectivity remain of paramount importance to allocators.